Shares of Intuitive Surgical (NASDAQ:ISRG) popped over 10% yesterday, after receiving great news that the FDA approved its new version of its surgical robot, the da Vinci Xi.
In this video, Motley Fool health-care analyst David Williamson looks through the various ways the Xi is superior to the previous model, the Si, and how those improvements could be a real catalyst for the stock going forward. David highlights the difficulties the stock has seen recently, from famed short-selling blog Citron Research's coming out with a bearish report on the company, to potential safety concerns cropping up. David also mentions that while he still sees Intuitive Surgical as the best pure play in robotic surgery, he does potentially still have some concerns.
Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind it is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Intuitive Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.